June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Assessment of retinal perfusion using ultra wide filed (UWF) imaging in patients with diabetic retinopathy treated with intravitreal bevacizumab (IVB)
Author Affiliations & Notes
  • Shulamit Schwartz
    Ophthalmology, Denver Health Medical Center affiliated with University of colorado, Denver, CO
  • Scott Oliver
    ophthalmology, University of Colorado, Aurora, CO
  • Regina Victoria
    Ophthalmology, Denver Health Medical Center affiliated with University of colorado, Denver, CO
  • Ramanath Bhandari
    Ophthalmology, Denver Health Medical Center affiliated with University of colorado, Denver, CO
  • Naresh Mandava
    ophthalmology, University of Colorado, Aurora, CO
  • Hugo Quiroz-Mercado
    Ophthalmology, Denver Health Medical Center affiliated with University of colorado, Denver, CO
  • Footnotes
    Commercial Relationships Shulamit Schwartz, None; Scott Oliver, Genentech (F), Ophthotech (F), Thrombogenics (F); Regina Victoria, None; Ramanath Bhandari, None; Naresh Mandava, genentech (F), thrombogenics (F); Hugo Quiroz-Mercado, Allegro Pharmaceutical (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 199. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Shulamit Schwartz, Scott Oliver, Regina Victoria, Ramanath Bhandari, Naresh Mandava, Hugo Quiroz-Mercado; Assessment of retinal perfusion using ultra wide filed (UWF) imaging in patients with diabetic retinopathy treated with intravitreal bevacizumab (IVB). Invest. Ophthalmol. Vis. Sci. 2013;54(15):199.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate retinal perfusion in diabetic retinopathy before and after treatment with monthly IVB injections over a medium term follow up, using UWF retinal imaging.

 
Methods
 

A retrospective, interventional, non comparative case series. Diabetic patients with newly diagnosed proliferative diabetic retinopathy (PDR) and/or macular edema (ME) were included. All were treated with IVB injections every 4-6 weeks, if pan retinal photocoagulation (PRP) could be deferred for at least four weeks at physician discretion. Patients with previous treatment with laser or angiogenic therapy, media opacity or PDR complications were excluded. Follow up included fluorescein angiography (FA) using UWF laser scanning ophthalmoscope technology (Optomap 200Tx, Optos®) that allowed for high resolution visualization of the retina up to 200 degree in one frame. The main outcome measure was the extent of retinal perfusion . Secondary outcomes were regression of neovascularization (NV), macular ischemia, BCVA and need for PRP or vitrectomy.

 
Results
 

Twelve eyes of six patients were enrolled in the study. Mean age was 54.8± 8.1 years. Eleven eyes were diagnosed with PDR and eight eyes with ME. Patients received on average 3 injections and followed for an average of 16.5 ± 3.2 weeks. IVB allowed for regression of NV in 11 eyes, demonstrated on FA a month after first injection. The average ischemic area decreased significantly from 86.2%± 4.9% to 77.2%± 10.7% and the average perfused area increased significantly by 66.5% (P=0.0024) during the follow up period. Two eyes showed minimal reduction in ischemic area after treatment and one of them developed mild persistent vitreous hemorrhage without evidence of active NV. Macular ischemia didn't evolve in any of the study eyes . None of the eyes developed DR complications that required rescue with PRP or vitrectomy. Average BCVA improved significantly from 0.48 log MAR before to 0.26 log MAR after treatment (p=0.0036).

 
Conclusions
 

IVB injections improved retinal perfusion in a small series of patients with DR over a medium term follow up. Further prospective large scale studies are needed to determine the role of IVB in PDR.

 
 
Patient # 1, 56y M, OD. Before (panel a & b) and 4.5 weeks (panel c), 16.5 weeks (panel d) after treatment.
 
Patient # 1, 56y M, OD. Before (panel a & b) and 4.5 weeks (panel c), 16.5 weeks (panel d) after treatment.
 
 
Patient # 5, 62y M. Panel a & b before and panel c & d 18.4 weeks after treatment.
 
Patient # 5, 62y M. Panel a & b before and panel c & d 18.4 weeks after treatment.
 
Keywords: 499 diabetic retinopathy • 748 vascular endothelial growth factor • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound)  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×